Serum Beta‐Synuclein Is Higher in Down Syndrome and Precedes Rise of pTau181

Autor:	Patrick Oeckl, Olivia Wagemann, Steffen Halbgebauer, Sarah Anderl‐Straub, Georg Nuebling, Catharina Prix, Sandra V. Loosli, Elisabeth Wlasich, Adrian Danek, Petra Steinacker, Albert C. Ludolph, Johannes Levin, Markus Otto
Rok vydání:	2022
Předmět:	Adult Amyloid beta-Peptides beta-Synuclein Neurology Case-Control Studies diagnosis [Alzheimer Disease] Humans tau Proteins ddc:610 Neurology (clinical) Down Syndrome Biomarkers
Zdroj:	Annals of neurology 92(1), 6-10 (2022). doi:10.1002/ana.26360
ISSN:	1531-8249 0364-5134
Popis:	This exploratory case-control study investigates the synaptic marker beta-synuclein in serum and plasma pTau181 in adults with Down syndrome (DS) with (sDS, n = 14) and without (aDS, n = 47) clinical symptoms of Alzheimer disease (AD) as well as euploid controls (n = 23). Beta-synuclein was higher in aDS and more pronounced in sDS (p < 0.0001), whereas pTau181 was only higher in sDS (p < 0.0001). Both markers showed good discriminatory power (area under the curve > 0.90) to distinguish symptomatic from asymptomatic AD. The data indicate that synaptic alterations belong to the earliest AD-associated events in DS and highlight the value of serum beta-synuclein as a potential early marker of AD. ANN NEUROL 2022.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e2e5f21f285ba45439bb36c7bb6d9f6 https://doi.org/10.1002/ana.26360 Zobrazit plný text záznamu Plný text